Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4793-4799

  Dolton, Michael J ^a   Ray, John E ^b   Chen, Sharon C A ^a   Ng, Kingsley ^c   Pont, Lisa G ^a   McLachlan, Andrew J ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ESOMEPRAZOLE; GLUCOCORTICOID; METHYLPREDNISOLONE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFAMPICIN; VORICONAZOLE;

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ARTICLE; AUDITORY HALLUCINATION; AUSTRALIA; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; VISUAL HALLUCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AUSTRALIA; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; MITOSPORIC FUNGI; MYCOSES; NUCLEIC ACID SYNTHESIS INHIBITORS; PHENYTOIN; PYRIMIDINES; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TRIAZOLES; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84865423887     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00626-12     Document Type: Article

References (34)

1. Andes D, Marchillo K, Stamstad T, Conklin R. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169. (Pubitemid 37229574)
2. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
3. Blume H, Donath F, Warnke A, Schug BS. 2006. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 29:769-784. (Pubitemid 44352242)
4. Boyd AE, et al. 2004. Adverse reactions to voriconazole. Clin. Infect. Dis. 39:1241-1244. (Pubitemid 40169325)
5. Chen Y, Ferguson SS, Negishi M, Goldstein JA. 2003. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol. 64:316-324. (Pubitemid 36909995)
6. Chhun S, et al. 2007. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852:223-228. (Pubitemid 46839210)
7. Czock D, Keller F, Rasche FM, Häussler U. 2005. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44:61-98. (Pubitemid 40096038)
8. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
9. Derendorf H, et al. 1993. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J. Clin. Pharmacol. 33:115-123. (Pubitemid 23089632)
10. Faber OK, Mouridsen HT, Skovsted L. 1974. The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol. Toxicol. (Copenh.) 35:195-200.
11. Heinz WJ, et al. 2007. Comparison of plasma trough concentrations of voriconazole in patients with or without comedication of ranitidine or pantoprazole. Clin. Microbiol. Infect. 13(Suppl 1):S357.
12. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
13. Hope WW. 2012. Population pharmacokinetics of voriconazole in adults. Antimicrob. Agents Chemother. 56:526-531.
14. Imhof A, Schaer DJ, Schanz U, Schwarz U. 2006. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly. 136:739-742. (Pubitemid 46032197)
15. Johnson LB, Kauffman CA. 2003. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36:630-637. (Pubitemid 36259570)
16. Li X-Q, Andersson TB, Ahlström M, Weidolf L. 2004. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos. 32:821-827. (Pubitemid 38955611)
17. Mavridou E, Bruggemann RJM, Melchers WJG, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
18. Mitsani D, et al. 2012. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob. Agents Chemother. 56:2371-2377.
19. Miyakis S, van Hal SJ, Ray J, Marriott D. 2010. Voriconazole concentrations and outcome of invasive fungal infections. Clin. Microbiol. Infect. 16:927-933.
20. National Cancer Institute, National Institutes of Health. 14 June 2010. Common terminology criteria for adverse events (CTCAE), version 4.03. NIH publication no. 09-5410. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11. pdf.
21. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
22. Pascual A, et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
23. Pfizer, Inc. 2011. Vfend prescribing information. Pfizer, New York, NY. http://labeling.pfizer.com/ShowLabeling.aspx?id=618.
24. Scholz I, et al. 2009. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br. J. Clin. Pharmacol. 68:906-915.
25. Smith J, et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
26. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243. (Pubitemid 43146453)
27. Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663. (Pubitemid 43990568)
28. Trifilio S, et al. 2005. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 35:509-513. (Pubitemid 40403355)
29. Trifilio S, et al. 2007. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109:1532-1535.
30. Trifilio S, et al. 2007. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 40:451-456. (Pubitemid 47288224)
31. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55:4782-4788.
32. Ueda K, et al. 2009. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int. J. Hematol. 89:592-599.
33. Weiss J, et al. 2009. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 49:196-204.
34. Wood N, et al. 2003. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl 1):56-61. (Pubitemid 37491735)